Cingulate Inc. (CING)
CING trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CING on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001862150 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These uncertainties raise substantial doubt about our ability to continue as a going concern for one year after the issuance date of our financial statements." | 10-Q 2026-11-13 |
| Cash and burn | $28.4M cash; operating cash flow -$5.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | 14,963,080 (2026-11-13); 6,757,070 a year earlier; 18,740,006 three years earlier. 3y figure adjusted for splits (1-for-240 overall). | Cover page 2026-11-13 |
| Reverse splits, 3 years | 2; latest 1-for-12 on 2024-08-09 | Source 2024-08-09 |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-01-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Kansas City, Missouri, United States | PCAOB Form AP 2026-04-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $657K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$5.9M | -$5.9M | $28.4M | $5.1M | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$9.3M | -$6.9M | $25.9M | $6.1M | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2025 2025-12-31 | Not filed | -$6.3M | -$3.6M | $11.0M | $6.3M | Needs four quarters | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | Not filed | -$7.3M | -$4.2M | $6.1M | $3.2M | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$5.0M | -$4.8M | $8.9M | $5.1M | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$3.9M | -$4.6M | $9.5M | $4.1M | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | Not filed | -$6.2M | -$4.1M | $12.2M | $2.5M | Needs four quarters | 10-K 2026-03-18 |
| Q3 2024 2024-09-30 | Not filed | -$4.1M | -$3.9M | $10.0M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-13 |
| Latest annual report | 10-K | 2026-03-18 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEF 14A | 2026-05-29 |
Source: SEC EDGAR submissions feed, 497 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.9% |
| 1 month | -8.9% |
| 3 months | -13.8% |
| Year to date | -0.9% |
| 1 year | +29.1% |
| From 52-week high | -63.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| CINGW | Cingulate Inc. Warrants | $0.0018 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INCR | Intercure Ltd. | $3.63 | -4.22% | $54.5M |
| AZR | Azora Therapeutics Inc. | $3.81 | -6.85% | $54.4M |
| XLO | Xilio Therapeutics Inc. | $7.70 | -3.08% | $54.4M |
| VRCA | Verrica Pharmaceuticals Inc. | $3.20 | -10.11% | $55.0M |
| HRTX | Heron Therapeutics Inc. | $0.2843 | -8.44% | $54.1M |
| SPRO | Spero Therapeutics Inc. | $0.9464 | -5.35% | $55.1M |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $2.88 | -4.32% | $56.0M |
| XBIT | XBiotech Inc. | $1.85 | -5.37% | $56.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier